SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAIVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1

被引：2

作者：

Feld, J. J. ^{[1
]}

Kowdley, K. V. ^{[2
]}

Coakley, E. ^{[3
]}

Sigal, S. ^{[4
]}

Nelson, D. ^{[5
]}

Crawford, D. ^{[6
,7
]}

Weiland, O. ^{[8
]}

Aguilar, H. ^{[9
]}

Xiong, J. ^{[3
]}

DaSilva-Tillmann, B. ^{[3
]}

Larsen, L. ^{[3
]}

Podsadecki, T. ^{[3
]}

机构：

[1] Toronto Western Hosp, Ctr Liver, Toronto, ON M5T 2S8, Canada

[2] Virginia Mason Med Ctr, Inst Digest Dis, Seattle, WA 98101 USA

[3] AbbVie Inc, N Chicago, IL USA

[4] NYU Langone Med Ctr, New York, NY USA

[5] Univ Florida, Coll Med, Gainesville, FL USA

[6] Gallipoli Med Res Fdn, Greenslopes, Qld, Australia

[7] Univ Queensland, Brisbane, Qld, Australia

[8] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Stockholm, Sweden

[9] Louisiana Res Ctr LLC, Shreveport, LA USA

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(14)60062-3

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

060

引用

页码：S25 / S25

页数：1

共 34 条

[1] SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naive Adults With Hepatitis C Virus Genotype 1
Kowdley, Kris V.
Feld, Jordan J.
Coakley, Eoin
Sigal, Samuel
Nelson, David R.
Crawford, Darrell
Weiland, Ola
Aguilar, Humberto
Xiong, Junyuan
DaSilva-Tillmann, Barbara
Larsen, Lois
Podsadecki, Thomas
GASTROENTEROLOGY, 2014, 146 (05) : S912 - S913
[2] SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
不详
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S1
[3] SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1
Jacobson, Ira M.
Zeuzem, Stefan
Baykal, Tolga
Marinho, Rui T.
Poordad, Fred
Bourliere, Marc
Sulkowski, Mark
Wedemeyer, Heiner
Tam, Edward
Desmond, Paul V.
Jensen, Donald M.
Di Bisceglie, Adrian M.
Varunok, Peter
Hassanein, Tarek
Xiong, Junyuan
DaSilva-Tillmann, Barbara
Larsen, Lois
Podsadecki, Thomas
GASTROENTEROLOGY, 2014, 146 (05) : S904 - S904
[4] Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates ≥90% in Treatment-Naive Adults Infected With Hepatitis C Virus Genotype 1A
Bernstein, David
Lalezari, Jacob
Luo, Yan
Box, Terry D.
Younes, Ziad H.
Green, Sinikka
Bhandari, Bai R.
Sepe, Thomas
Cooper, Curtis
Tam, Edward
Tsai, Naoky
Hassanein, Tarek
Xie, Wangang
Podsadecki, Thomas
GASTROENTEROLOGY, 2014, 146 (05) : S977 - S978
[5] PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients
Andreone, Pietro
Colombo, Massimo
Enejosa, Jeffrey V.
Koksal, Iftihar
Ferenci, Peter
Maieron, Andreas
Muellhaupt, Beat
Horsmans, Yves
Weiland, Ola
Reesink, Henk W.
Rodrigues, Lino, Jr.
Hu, Yiran B.
Podsadecki, Thomas
GASTROENTEROLOGY, 2014, 146 (05) : S159 - S159
[6] A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection
Kowdley, Kris V.
Lawitz, Eric
Poordad, Fred
Cohen, Daniel E.
Nelson, David R.
Zeuzem, Stefan
Everson, Gregory T.
Kwo, Paul Y.
Foster, Graham R.
Sulkowski, Mark S.
Xie, Wangang
Pilot-Matias, Tami
Liossis, George
Larsen, Lois M.
Khatri, Amit
Podsadecki, Thomas J.
Bernstein, Barry
HEPATOLOGY, 2012, 56 (06) : 1515 - 1516
[7] Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study
Kowdley, Kris
Lawitz, Eric
Poordad, Fred
Cohen, Daniel
Nelson, David
Zeuzem, Stefan
Everson, Gregory
Kwo, Paul
Foster, Graham
Sulkowlski, Mark
Xie, Wangang
Larsen, Lois
Khatri, Amit
Podsadecki, Thomas
Bernstein, Barry
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S108 - S108
[8] Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions
Cohen, Daniel E.
Xie, Wangang
Larsen, Lois
Marincic, Christal
Knauss-Townsend, Mary
Khatri, Amit
Podsadecki, Thomas
Bernstein, Barry
HEPATOLOGY, 2013, 58 : 754A - 755A
[9] Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders
Lawitz, Eric
Hezode, Christophe
Varunok, Peter
Thuluvath, Paul J.
Baykal, Tolga
Kapoor, Mudra
Lovell, Sandra S.
Wang, Tianli
Pilot-Matias, Tami
Vilchez, Regis A.
Bernstein, Barry
HEPATOLOGY, 2013, 58 : 244A - 244A
[10] RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267+ABT-333+RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION
Kwo, P.
Mantry, P.
Coakley, E.
Te, H.
Vargas, H.
Brown, R., Jr.
Gordon, F.
Levitsky, J.
Terrault, N.
Burton, J., Jr.
Xie, W.
Setze, C.
Badri, P.
Vilchez, R. A.
Forns, X.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S47 - S48

← 1 2 3 4 →